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Decay-accelerating factor (OAF) is a 70-kO membrane gly-
coprotei n that regulates auto logous complement activation, 
by preventing assemb ly of alternative or cl assical C3/C5 
convertases, and has been shown to have a wide tissue distri-
bu tion. In this study , OAF antigen has been demonstrated at 
the intercellular spaces of normal human epidermis with 
monoclona l antibody against OAF using the peroxidase -
anti-peroxidase method. The amount of OAF was greater at 
the granular layer th an th e basa l cel l layer as judged by inten-
sity of the staining. Western blot analysis of OAF in the 
epidermis showed a 55-kO band, whereas that of buffy coat 
ce lls was approximately 67 kO. When OAF of the epidermis 
was treated with neuraminidase, the molecular weight was 
I n bullous pemphigoid, pemphi gus vu lgaris , or pemphigus fo liaceus, com plement is activated in the skin, which results in the deposition of membrane attack complex (MAC) of complement at the lesional skin (1 ,2]. The membrane integ-rity of a cel l is lost by deposition of MAC on the cell mem-
brane, w hich may contribute to blister formation (2] . The mecha-
nism th at prevents co mplement activation in the normal human 
skin is not clear. The existence of OAF on the elas tic fibers (3] may 
explain one of the mechanisms that regulate complement-mediated 
tissue destruction in the normal skin. 
OAF is a 70-kD membrane glycoprotein that inhibits comple-
ment-mediated cel l lysis, by preventing assembly of the alternative 
or classica l C3 and CS convertases ( 4- 6]. Human OAF was first 
described on the erythrocyte, but recently it has become evident that 
DAF is wide ly distributed throu ghout th e body , including on pe-
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Abbreviations: 
C R 1: complement receptor type 1 
OAF: decay-acce lerating factor 
MAC: membra ne attack complex 
MoAb: monoclonal an tibody 
MW: molecular weight 
NP-40: nonidet P-40 
PAP: peroxidase-anti-peroxidase 
PBS: 10 mM phosphate-buffered sa line, pH 7.4 
PI: phosphatidylinositol 
PIPLC: phosphatidylinositol-specific phospholipase C 
PMSF: phenylmethyl sulfonyl fluorid e 
SDS-PAGE: sod ium dodecy lsu lfate polyacrylamide ge l electrophores is 
TI3S: 20 mM tri s-buffered sa line, pH 7.4, co ntainin g 500 mM NaCI 
reduced to 53 kO, whereas that ofbuffy coat cells was 56 kO. 
These results indicated that the content of sia lic acid of OAF 
in the epidermis was different from that ofbuffy coat cells. In 
phosphatidylinositol-specific phospholipase C (PIPLC)-
treated normal human skin, OAF was not demonstrated in 
the epidermis, whereas OAF remained unchanged on the 
elas tic fibers. After the treatment of the epidermis by PIPLC, 
OAF was released into th e buffer shown by Western blot 
analysis. These results suggested that OAF on the epidermis 
was anchored to keratinocyte vi~ phosphatidylinositol (PI) , 
whereas the anchonng mechamsm of OAF on the elastic 
fibers was not through PI.] In 11est D erma.to/96:61-64, 1991 
ripheral blood ce ll s, su rface of cornea, mucous membrane, and g lan-
dular ce ll s, as well as plasma, secretory fluids, and urine (7] . 
To study th e mechanisms to prevent co mplement act ivat ion in 
the human sk in , OAF on the human epidermis was stud ied and the 
first evidence of ex istence of OAF was demonstrated on human 
keratinocytes with its uniqu e profile. 
MATERIALS AND METHODS 
Immunohistochemical studies Four-micrometer-thick sec-
tions were cut ou t from normal human sk in , obtained from plastic 
surgery, and were frozen at -70oC in OCT compound (Miles Inc., 
Elkhart, IN) . The tissue sections were fix ed with acetone/chloro-
fo rm (1 : 1) at -20 °C for 9 min. Staining with PAP kit (Ortho 
Diagnostic Systems Inc., Raritan, NJ) were performed according to 
the instructions provided by the I:-Janu facture r. Briefly, after block-
ing with normal r:~bbit serum, 0.1,ug/ ml of MoAb anti-OAF IgG2a 
(IA 10 (8]), a generous gift from Dr. Taroh Kinoshita of Osaka 
University, or as a co ntrol anti-C R1 (Becton Dickinson, Mountain 
View, C A) in PBS containing 1% bovine serum albumin was added 
to th e sections and incubated at room tempefature in a moist 
chamber for 1 h. Second antibody and PAP were reacted to the 
specimens, seq uentiall y. 
Preparation of Epidermis and Buffy Coat Cells N ormal 
human skin, obtained from plastic surgery, was incubated with 20 
mM EDTA in PBS, pH 7.4 , at 37"C for 2 h to separate the epider-
mis. Separated epidermis was disrupted with Ultrasonic Disrupter 
(Eiko Co., Tokyo, J apan) 111 PBS co ntaining protease inhibitors {20 
mM EDTA, 1 mM PMSF, and 5 mM benza midine) at o oc and 
washed 3 times with the same buffer. 
Buffy coat cell membrane was prepared as follows. Fifty milli-
li ters of blood was drawn from a hea lth y volunteer into a syringe 
contammg 1 ml ofO.S M EDTA and 2.5 ml of 6.0% dextran (Sigma 
C hemica l o., St. Louis, MO) m 0.9% N aC I. The syringe was 
Inverted and left at room temperature for 1 h. Buffy coat ce lls in the 
supern:~tant were wash ed with PBS and the remaining erythrocytes 
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were removed by hypoto nic lysis. After was hin g, buffy coat cell 
suspension was disrupted in PBS containing protease inhibitors for 
1 min at 0° C and centrifuged for 10 min at 1000 rpm to remove th e 
nucleus. The supernatant was centrifuged at 14,000 rpm for 
10 min. T he pell ets were was hed and frozen at - 70 oC until use. 
Western Blot Analysis Soluble fraction was extracted from the 
disrupted human epidermis or buffy coat cell membrane by incuba-
tion with 2% N P-40 in PBS containing protease inhibitors at o oc 
for 30 min . Extrac ted proteins, separated by centrifu gation at 
14 ,000 rpm fo r 15 min, were subjected to a 7.5% SDS-~AGE and 
transferred to nitrocellulose paper at 30 V and left overn1ght. Re-
maining protein binding sites on th e nitrocellulose paper were 
blocked with 3% gelatin in TBS, followed by incubation with 1 
,ugjml of MoAb anti-DAF in T BS containing 1% gelatin and 0.05% 
T ween-20. Bound IgG was detected w ith 1 : 3000 dilution of goat 
anti-mouse IgG, alkaline phosphatase conju gated (Bio Rad Labora-
tories, Richmond, C A). As a standard , prestained MW marker (Bio 
Rad Laboratories) was used. 
Neuraminidase Treatment of DAF DAF was ex trac ted from 
the d isrupted epidermis or the membrane frac tion ofbuffy coat cells 
w ith 2% NP-40 in 20 mM tris maleate containing 1 mM calcium 
acetate and 10 mM galactono lactone, pH 6.0, at ooc for 30 min. 
N euraminidase (type VI; Sigma) was added to the extractions at a 
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concentration of 10 U / ml and incubated at 37oC for 1 h (9]. MW 
of DAF was de termined by W estern blo t analysis as described above. 
PIPLC Treatment ofNormal Human Skin After washin g the 
sections of normal human sk in with PBS, 0.1 U / ml of phospha-
tidylinosito l-specific p hospholipase C (PIPLC) (American Radio-
labeled C hemicals Inc., St. Louis, M O ) in PBS or PBS alone was 
added to each section and incubated at 37°C fo r 30 min. Remaining 
DAF on th e sections was stained w ith MoAb anti-DAF as described 
above. 
For W estern bl ot analysis, disrupted human epidermis was 
trea ted w ith PIPLC. After washing w ith PBS, th e pellets of epider-
mis were incubated w ith 0.1 U / ml of PIPLC in PBS or PBS alone at 
37"C for 30 min, fo llowed by centri fugation at 14,000 rpm for 
15 min to separate th e supernatants and the pell ets. After washing 
with PBS, remaining DAF on the pell ets was further extracted with 
2% NP-40 in PBS as described above. OAF in the supernatants or 
th e ex trac ts were detected by W estern blot analys is as described 
above. 
RESULTS 
Distribution of DAF in the Normal Human Skin N ormal 
human skin sections were stained w ith anti-DAF using PAP. OAF 
was fo und both in the interce llular spaces of epidermis and on the 
fibers of dermis as shown in Fig 1A- C. T he intensity of. th e staining 
pattern was higher at the gran ul ar layer th an at th e basa l cell layer. 
Fig ure 1. Staini ng of normal human sk in wi th M oAb anti- OAF. N ormal human sk in sections were stained with MoAb anti OAF {A -C) or M oAb anti CRI 
(D) usin g PAP. A, D: magnifi ca tion X 40. B: a hi gher magnifi ca tion of the epidermis, X 160 . C: a higher magnifi cation o f the clasti c fibers in reticular dermi. 
X80. 
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Figure 2. W es tern blot ana lysis of cell ex tracts. The soluble fraction was 
extracted from th e disrupted human epidermis (la11es 1- 4) or the buffy coat 
cell membrane (la11 es 5 -7) by incubation with 2% NP-40 in th e presence of 
pro tease inhibitors at O'C for 30 min. Extracted proteins were treated with 
10 U / ml of neuraminidase at 37 'C for 1 h (la11es 3 and 7) , or buffer alone 
(lan es 2 and 6) . La11es 1,4, a.1d 5 were not treated. These samples were 
subjected to a 7.5% SOS-PAGE and transferred to mtroce ll ulose paper. La11es 
1 _ 3 and 5-7 were reacted with MoAb anti-OAF, and la11 e 4 was reacted with 
MoAb anti-C R 1. Bound MoAb was detected with goa t anti -mouse IgG , 
alkaline phosphatase conjugated. La11e 8, prestained MW marker. 
M eanwhi le, CR1 was not detected either in the epidermis and the 
dermis (Fig 1D). 
Western Blot Analysis DAF of the buffy coat cells had a M W of 
approximately 67 kD (Fig 2, la 11e 5), whereas DAF of the epidermis 
appeared at 55 kD (lane 1) . The MW ofDAF in the buffy coat cells 
showed 56 kD after treating with 10 U/ ml neuraminidase at 37 ' C 
fo r 1 h (fa,.,e 7), whereas that of epidermis was reduced only from 55 
kD to 53 kD (lane3) . 
PIPLC Treatme11t o{Normal Skin Sections N on!ul human skin sec-
t ions were treated with 0.1 U / ml of PIPLC m PBS (Fig 3A) or 
buffer alone (Fig 3B) at 37 ' C for 30 min in a moist chamber. Re-
maining DAF on the sections was detected with MoAb anti-DAF 
using PAP.DAF in the epidermis was not demonstrated after the 
treatment, whereas DAF on the elastic fibers was unchanged (Fig 
3A). 
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PIPLC Treatment of Disrupted Human Epidermis 
Disrupted human epidermis was incubated w ith 0.1 U j ml of 
PIPLC in PBS or buffer alone at 37' C for 30 min. After separation 
of the supernatant by the centrifugation, the pellets were furth er 
extracted with 2% NP-40 in PBS at O'C for 30 mi n. DAF in both 
the supernatants and the extracts were subjected to W estern blot 
analysis using MoAb anti-DAF. A 55-kD band was detected in the 
supernatant of PIPLC-treated epidermis and in the supernatant of 
the buffer-treated epidermis, and a faint band was demonstrated in 
the pellet of PIPLC-treated epidermis (Fig 4) . On the other hand , 
nothing was detected in the supernatant of PBS-treated epidermis. 
The MW of these bands were similar in size. 
DISCUSSION 
In this study, we have shown that DAF was present on human 
keratinocytes and its distribution showed a unique profile. Immu-
nohistochemical study revealed that DAF was present in the epider-
mis, at the intercellu lar areas, implying that this antigen was asso-
ciated with keratinocyte cell membrane. The staining pattern 
showed predominant localization of DAF in the granular layer. 
Anti-DAF MoAb also reacted to fibers in the dermis , which were 
considered to be elastic fibers as previously shown by W erth et al (3]. 
To confirm the presence of DAF on the epidermis, W estern blot 
analysis was performed. The MW of DAF in epidermis showed a 
55-kD band , whereas that of buffy coat cells was approximately 67 
kD. The MW ofDAF on buffy coat cell is slightly smaller than that 
in the previous reports (8], p erfo rmed by immunoprecipitation and 
autoradiography. The difference may be due to the differe nt 
method used to determine MW or the MW marker for SDS-PAGE. 
H owever, 55-kD DAF has not been reported so far. 
DAF is first synthesized as a 43-kD precursor, and after several 
modifications the molecule becomes approximately 70-kD (9] . Ma-
ture DAF possesses multiple, highly sialated 0-linked oligosaccha-
ride side chains and one N-linked complex-type oligosaccharide 
side chain (9]. To study the structure of 55-kD DAF, DAF was 
treated with neuraminidase, an enzyme known to cleave sialic acid . 
The MW of DAF on erythrocyte was reduced to 55 kD after the 
neuraminidase treatment (9] . In our study, neuraminidase treatment 
produced a decrease of 11 kD in MW of DAF extracted from buffy 
coat cell s, and of only 2 kD in those from the epidermis. These 
results indicated that the reduction of MW of OAF was at least in 
part due to the content of sialic acid. The structure of the oligosac-
Fi~ure 3. PIPLC treatment of normal human skin. Frozen section of normal human skin was trea ted ~ith 0.1 U / ml PIPLC in PBS (A} or PBS alone (B) at 
37 C for 30 mm . After washmg, remauung OAF was stamed With MoAb ann-OAF as descnbed 111 F1g 1 (magnifi ca tion X 40) . 
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Figure 4. PIPLC trea tmem of disrupted human epidermis. Disrupted 
human epidermis was treated w ith 0. 1 U / ml PIPLC in PBS or PBS alone at 
37"C fo r 30 min . After separatio n of the supernatant by centrifugation, the 
pell et was washed w ith PBS and further ex tracted w ith 2% NP-40 in PBS 
containing protease inhibi tors at o•c for 30 min . DAF in the supernatan t or 
the ex tracts were detected by Western blot ana lysis as in Fig 2. Ln11e 1, pellet 
of PBS-treated epidermis. Ln11e 2, supernatant of PBS-treated epidermis. 
La11e 3, pellet of PIPLC-treated epidermis. Ln11e 4, supernatant o f PIPLC-
treated epidermis. Ln11e 5, prestained MW marker. 
charide side chain of DAF on epidermis may be different from that 
of buffy coat cells. 
DAF is anchored to th e cell membrane via a glycolipid mo iety 
containin'g PI , and is removed by PIPLC (10,11 ). T he MW of 
rel eased OAF is slightl y small er th an cell -associated DAF [11). The 
prese nt immunohistochemica l studies showed a reducti on of DAF 
from the epidermis after the PIPLC treatment. In co ntrast to that o n 
th e epidermis, DAF on elastic fibers remained unchanged , indicat-
ing either th at DAF o n elas ti c fibers was not anchored via PI or that 
DAF w ithin the micro fibril s of elas tin was not accessibl e to the 
enzyme [3]. W estern blot analys is showed that DAF was released 
into the supernatant by the PIPLC treatment, but appare nt reduc-
tion of MW was not detected. 
In concl usion, DAF is co nsidered to be anchored to ce ll mem-
brane of kerati nocytes via PI and its sia lic acid content may be much 
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less than th at of the buffy coa t cell s. Althou gh DAF on kera rino-
cy tes and elas tic fibers is a likely regulator of C3 and CS convertases 
in th e sk in, furth er analys is .of biologic signifi cance and pathologic 
chan ges remains to be studied to elucidate its precise role in prevent-
ing tissue destruction from autologous complement . 
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